Stockscreener 앱 받기
1.03
0.98%
0.01
시간 외 거래:
1.03
전일 마감가:
$1.02
열려 있는:
$1.03
하루 거래량:
3.83M
Relative Volume:
0.80
시가총액:
$198.79M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-0.9626
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
+0.98%
1개월 성능:
-3.74%
6개월 성능:
-59.29%
1년 성능:
-77.16%
1일 변동 폭
$0.97
$1.035
1주일 범위
$0.9581
$1.15
52주 변동 폭
$0.91
$4.85
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.03 | 196.86M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Pharma News: What are the analyst revisions for Air T IncIs Humacyte Inc stock a good investment in YEAR2025 Short Interest & Community Verified Swing Trade Signals - baoquankhu1.vn
Smart Money: What is the target price for Humacyte Inc Equity Warrant stockRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Rate Cut: What is the target price for Humacyte Inc Equity Warrant stockNew Guidance & Daily Growth Stock Tips - baoquankhu1.vn
Aug Swings: Whats the fair value of Humacyte Inc Equity Warrant stockJuly 2025 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Stop Loss: Will Humacyte Inc benefit from rising consumer demandRisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Volatility Watch: What are Humacyte Incs technical support levelsTrade Analysis Summary & Community Supported Trade Ideas - baoquankhu1.vn
Humacyte (NASDAQ:HUMA) Given New $10.00 Price Target at Benchmark - MarketBeat
Benchmark lowers Humacyte stock price target to $10 on Israel filing plans - Investing.com India
Humacyte Stock (HUMA) Opinions on Recent Price Surge - Quiver Quantitative
Whale Trades: Whats the fair value of Humacyte Inc stock2025 Price Momentum & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 614% Upside in the Biotech Sector - DirectorsTalk Interviews
Published on: 2026-01-15 08:53:32 - baoquankhu1.vn
Analyst Upgrade: Can Humacyte Inc. stock maintain growth trajectoryTrade Signal Summary & Weekly Momentum Picks - Bộ Nội Vụ
CEO Moves: What catalysts could drive Humacyte Inc. stock higherPortfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Humacyte, Inc. (NASDAQ:HUMA): Are Analysts Optimistic? - Yahoo Finance
Quarterly Risk: Does Humacyte Inc Equity Warrant stock benefit from AI growthPortfolio Return Report & Verified Swing Trading Watchlists - baoquankhu1.vn
While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most - simplywall.st
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Is Humacyte Inc. Equity Warrant stock undervalued vs historical averagesTrail vs Road Selection & quick comparison of popular models - ulpravda.ru
How buybacks impact Humacyte Inc. Equity Warrant stock valueJuly 2025 Gainers & Entry Point Confirmation Alerts - ulpravda.ru
Will Humacyte Inc. Equity Warrant stock gain from lower inflationPortfolio Gains Report & Fast Gaining Stock Reports - ulpravda.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 571.55% Upside in the Biotech Sector - directorstalkinterviews.com
Is Humacyte Inc. Equity Warrant stock a contrarian buyQuarterly Growth Report & Real-Time Volume Spike Alerts - ulpravda.ru
Will Humacyte Inc. stock recover faster than peersJuly 2025 Movers & Reliable Intraday Trade Alerts - ulpravda.ru
Can Humacyte Inc. Equity Warrant stock resist market sell offsOptions Play & Fast Gain Swing Trade Alerts - ulpravda.ru
Winners Losers: Can Humacyte Inc. stock deliver sustainable ROE2025 Sector Review & AI Enhanced Trading Alerts - ulpravda.ru
Form 8-KCurrent report - ADVFN
What sentiment indicators say about Humacyte Inc. stockMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Can Humacyte Inc. stock sustain revenue growthJuly 2025 Volume & Verified Chart Pattern Trade Signals - ulpravda.ru
How strong is Humacyte Inc. Equity Warrant stock revenue growthMarket Performance Report & Precise Buy Zone Identification - ulpravda.ru
Can Humacyte Inc. stock deliver sustainable ROEQuarterly Market Summary & AI Driven Stock Reports - ulpravda.ru
Today's Analyst Ratings: Humacyte (HUMA) Maintains "Buy" Rating - GuruFocus
Humacyte enters sales agreement with TD Securities - MSN
Preventable surgery complications can drive hospital charges toward $600K - Stock Titan
Patterns Watch: Can Humacyte Inc stock deliver sustainable ROESwing Trade & Risk Managed Investment Signals - moha.gov.vn
Humacyte, Inc.Common Stock (NQ: HUMA - FinancialContent
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - marketscreener.com
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - marketscreener.com
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com Australia
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Humacyte, Inc. (HUMA) Stock Analysis: Exploring A Potential 718% Upside In Biotechnology - DirectorsTalk Interviews
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):